Assess whether pediatric studies are necessary or waivable (a353ab)

Situation

A company with a CMC site change mid-review cannot treat a CMO 483 that maps to the NDA CMC module as color commentary on complete-response-letter deficiency list. Labeling negotiator must close pediatric studies are necessary from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

Labeling negotiator in a company with a CMC site change mid-review must choose Pediatric studies are necessary / Waivable using complete-response-letter deficiency list after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• Complete-response-letter deficiency list reads as Pediatric studies are necessary once a CMO 483 that maps to the NDA CMC module is lined up to the same Pharma & Life Sciences population.
• Complete-response-letter deficiency list is closer to Waivable after a CMO 483 that maps to the NDA CMC module; Pediatric studies are necessary would over-claim this Pharmacovigilance extract.
• A dual reading is still live in complete-response-letter deficiency list for labeling negotiator in a company with a CMC site change mid-review.
• Complete-response-letter deficiency list is missing the fact labeling negotiator needs after a CMO 483 that maps to the NDA CMC module; stop this Pharma & Life Sciences close.

Analysis required

• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a CMO 483 that maps to the NDA CMC module.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read complete-response-letter deficiency list against a CMO 483 that maps to the NDA CMC module and write the one fact that would move pediatric studies are necessary for labeling negotiator.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Pharmacovigilance packet (complete-response-letter deficiency list after a CMO 483 that maps to the NDA CMC module). The follow-on Pharmacovigilance action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.